IN Brief:
- DMK Group has commissioned a €25m lactoferrin production plant at Altentreptow in Germany.
- The project includes a 655 sq m production building, a 130 sq m chromatography facility, and a 30 m elevated walkway linking the new assets to the existing site.
- The investment moves DMK further into high-value bioactive milk proteins used in specialised nutrition, health, and pharmaceutical applications.
DMK Group has commissioned a new lactoferrin production plant at its Altentreptow site in Germany, marking a €25m expansion into a specialised dairy ingredients segment with high technical and regulatory barriers.
The plant has been developed to manufacture lactoferrin, a bioactive milk protein used in specialised nutrition, health, pharmaceutical, and early-life nutrition applications. Commercial market launch of the lactoferrin powder produced at the site is scheduled for autumn 2026.
At Altentreptow, the project expands DMK’s industrial capability and gives the cooperative a new strategic business segment beyond conventional dairy processing. Lactoferrin production requires advanced separation and purification expertise, stable quality systems, and tightly controlled specifications, particularly where ingredients are intended for sensitive nutrition and health applications.
The investment includes a new production building with a floor area of around 655 sq m, housing the new production facilities. DMK has also added a separate 130 sq m building for chromatographic applications, strengthening the purification infrastructure needed for specialised protein processing. A 30 m elevated walkway connects the new building with existing factory infrastructure, helping maintain site traffic flow and operational continuity.
Commissioning began in December 2025, allowing the company to move through process validation and market-readiness work ahead of commercial supply. The project brings together process engineering, dairy science, and ingredient-market development in a category where quality consistency and documentation are central to customer acceptance.
Lactoferrin occupies a different position in the dairy value chain from bulk milk powders, cheese, butter, and standard whey products. It is a higher-value ingredient where commercial success depends on purity, stability, traceability, safety systems, and application performance. The plant is therefore a processing investment as much as an ingredient-market expansion.
The development sits within a wider movement toward functionality and bioactive performance in dairy ingredients. Armor Protéines’ work on dairy functionality and precision fermentation shows how the category is stretching beyond commodity protein supply into more controlled, application-specific systems.
High-protein beverages, medical nutrition, sports nutrition, meal replacements, fortified dairy desserts, and products aimed at ageing consumers are all increasing demand for ingredients that do more than add protein content. In those formats, dairy ingredients must deliver nutrition, texture, heat stability, solubility, flavour compatibility, and shelf-life performance. Lactoferrin adds another layer because bioactive proteins are often used where regulatory, quality, and customer documentation standards are more demanding.
Altentreptow’s role is strategically important because dedicated production gives DMK greater control over product specification and process validation than a looser supply model would allow. Customers in nutrition and health markets need consistent industrial production, not only access to the ingredient. The more sensitive the application, the less tolerance there is for variation in quality, supply, or documentation.
The investment also shows how dairy cooperatives are looking for ways to increase milk value without relying entirely on higher commodity prices. Specialised proteins can support margin improvement, but they demand capital, technical capability, and market access. Not every dairy processor can move into lactoferrin because separation and purification requirements are demanding and the customer base expects strong evidence of performance and safety.
Precision fermentation is beginning to challenge parts of the dairy bioactives market by offering controlled routes to specific proteins, including lactoferrin. Conventional dairy processors still have advantages in milk sourcing, dairy know-how, established customers, and regulatory familiarity, but those advantages have to be backed by specialised production capability.
DMK’s investment strengthens its conventional dairy-derived lactoferrin capacity at a point when the market is becoming more technically sophisticated. The autumn 2026 market launch will test specification stability, documentation, application support, and supply reliability. If those elements hold, the Altentreptow plant gives the cooperative a stronger position in a segment where dairy processing, nutritional science, and regulated ingredient manufacturing increasingly overlap.
